Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Clinical trial NCT05201066 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05201066
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-28
- Primary completion
- 2028-02-14
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.